- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.05. | Leerink senkt Kursziel für Lexeo Therapeutics auf 10 US-Dollar, behält Ausblick bei | 1 | Investing.com Deutsch | ||
| LEXEO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.05. | Leerink cuts Lexeo Therapeutics price target to $10, maintains outlook | 1 | Investing.com | ||
| 27.05. | Lexeo Therapeutics raises $80M in private placement | 2 | Seeking Alpha | ||
| 27.05. | Lexeo Therapeutics Announces $80 Mln Private Placement Of Shares | - | RTTNews | ||
| 27.05. | Lexeo Therapeutics secures $80 million in private placement | 1 | Investing.com | ||
| 27.05. | Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases | 2 | GlobeNewswire (USA) | ||
| 27.05. | Lexeo Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.05. | Lexeo stock price target cut to $15 by H.C. Wainwright | 1 | Investing.com | ||
| 12.05. | Lexeo laid off 15% of staff in April to focus on lead cardiac gene therapies | 1 | FierceBiotech | ||
| 12.05. | Lexeo Therapeutics, Inc. Q1 Loss Increases, Misses Estimates | - | RTTNews | ||
| 12.05. | Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights | 176 | GlobeNewswire (Europe) | Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned... ► Artikel lesen | |
| 12.05. | Lexeo Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 01.05. | Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 08.04. | H.C. Wainwright maintains Buy rating on Lexeo Therapeutics stock | 4 | Investing.com | ||
| 07.04. | Lexeo locks in pivotal trial plan as clinical data pump up prospects of cardiac gene therapy | 2 | FierceBiotech | ||
| 07.04. | Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials | 1 | Benzinga.com | ||
| 07.04. | Lexeo Reports Positive Interim Data Across All Dose Cohorts Of LX2006 | 1 | RTTNews | ||
| 07.04. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.04. | Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study | 127 | GlobeNewswire (Europe) | Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner Clinically meaningful improvements in majority of participants... ► Artikel lesen |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,465 | +0,48 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants... ► Artikel lesen | |
| IMMUNITYBIO | 2,812 | +1,88 % | FDA grants expanded access to ImmunityBio's Anktiva for lymphopenia | ||
| ANAVEX LIFE SCIENCES | 6,900 | -4,85 % | Anavex Life Sciences Corp. Q2 Loss Beats Estimates | WASHINGTON (dpa-AFX) - Anavex Life Sciences Corp. (AVXL) released Loss for second quarter that beat the Street estimates.The company's earnings came in at -$11.20 million, or -$0.13 per share.... ► Artikel lesen | |
| ARDELYX | 3,279 | +1,67 % | Ardelyx, Inc.: Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer | WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
| AKEBIA | 3,498 | +0,52 % | Akebia Therapeutics, Inc.: Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology | CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,360 | -2,16 % | Protalix BioTherapeutics Inc. Q1 Loss Narrows | JERUSALEM (dpa-AFX) - Protalix BioTherapeutics Inc. (PLX) released Loss for first quarter of -$3.62 millionThe company's earnings came in at -$3.62 million, or -$0.05 per share. This compares... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 11,800 | +1,72 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025 | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place... ► Artikel lesen | |
| CORMEDIX | 11,600 | -5,69 % | CorMedix bei Jefferies Healthcare: Strategische Expansion und finanzielles Wachstum | ||
| ENZO BIOCHEM | 0,476 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 30.04.2025 | The following instruments on XETRA do have their last trading day on 30.04.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 30.04.2025ISIN NameCH0347556901 PFBK SCHW.HYP. 17-25... ► Artikel lesen | |
| NUVATION BIO | 2,475 | -0,20 % | JMP hält an 6 US-Dollar Kursziel für Nuvation Bio Aktie vor PDUFA fest | ||
| QUANTERIX | 5,380 | +4,06 % | Quanterix and Akoya Biosciences Announce Amended Merger Agreement | Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination
BILLERICA, Mass. & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company... ► Artikel lesen | |
| IMMIX BIOPHARMA | 2,370 | +8,22 % | Immix Biopharma - ASCO/KOL event reaffirms NXC-201's potential | Following Immix's update at the 61st annual American Society of Clinical Oncology conference (ASCO 2025), the company hosted a key opinion leader (KOL) event, which showcased the potential of NXC-201... ► Artikel lesen | |
| BELITE BIO | 52,00 | -4,59 % | Belite Bio, Inc: Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease | Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant's efficacy and favorable safety profileTrial completion expected by Q4 2025 (including a... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report |
LEXEO THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,630 (+19,27 %) liegt der Kurs bei 3,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEXEO THERAPEUTICS INC finden Sie auf Wallstreet Online.